|
WITHDRAWN: Ovarian ablation for early breast cancer. |
50.00% |
|
Willmar Schwabe Award 2006: antiplasmodial and antitumor activity of artemisinin--from bench to bedside. |
80.00% |
|
Why We Get Sick And How to Get Well |
90.00% |
|
Why is not Ukrain approved yet in Austria/EU? |
98.57% |
|
Why cerebellar glioblastoma is rare and how that indicates adjunctive use of the FDA-approved anti-emetic aprepitant might retar |
|
|
Why are tumour blood vessels abnormal and why is it important to know? |
90.00% |
|
WHO’S AFRAID OF A CURE FOR CANCER? - The struggle for an alternative cancer drug |
90.00% |
|
Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. |
80.00% |
|
Vitamin D for cancer prevention: global perspective. |
90.00% |
|
Vitamin D Binding Protein-Macrophage Activating Factor Inhibits HCC in SCID Mice. |
80.00% |
|
Vitamin D binding protein-macrophage activating factor directly inhibits proliferation, migration, and uPAR expression of prosta |
90.00% |
|
Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. |
90.00% |
|
Vitamin D and prostate cancer risk: a review of the epidemiological literature. |
60.00% |
|
Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. |
60.00% |
|
Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases. |
90.00% |
|
Update on pilot study on antitumor efficacy of intravenously applied synergistic combinations of diflunisal, PAS, and aspirin in patients with advanced solid tumors. |
60.00% |
|
Update on pilot study on antitumor efficacy of intravenously applied synergistic combinations of diflunisal, PAS, and aspirin in patients with advanced solid tumors. |
90.00% |
|
Ukrain: Debated Subjects |
80.00% |
|
Ukrain: acute toxicity after intravenous, intramuscular and oral administration in rats |
40.00% |
|
Ukrain with chemotherapy in malignant melanoma (case report) |
50.00% |
|
Ukrain treatment in carcinoma of the oesophagus (case report) |
70.00% |
|
Ukrain treatment in carcinoma of the cervix (case report) |
60.00% |
|
Ukrain treatment in a patient with non-seminomatous germ-cell tumour of testis (case report) |
50.00% |
|
Ukrain treatment in a patient with metastatic renal cell carcinoma extending to the vena cava inferior. |
50.00% |
|
Ukrain treatment in a patient with breast carcinoma |
70.00% |
|
Ukrain therapy of stage T1N0M0 bladder cancer patients |
60.00% |
|
Ukrain therapy of recurrent breast cancer with lung metastases (case report) |
80.00% |
|
Ukrain therapy of a recurrent astrocytoma of the optic nerve (case report) |
20.00% |
|
Ukrain therapy in a frontal anaplastic grade III astrocytoma (case report) |
40.00% |
|
Ukrain monotherapy in malignant melanoma (case report) |
80.00% |
|
Ukrain in the treatment of urethral recurrent carcinoma (case report) |
50.00% |
|
Ukrain Debate 1: What is the active Substance of Ukrain? |
80.00% |
|
Ukrain both as an anti cancer and immunoregulatory agent |
60.00% |
|
Ukrain acts by inhibition of tubulin polymerization in normal and malignant cell lines. |
80.00% |
|
Ukrain - a new cancer cure? A systematic review of randomised clinical trials. |
90.00% |
|
Ukrain |
62.22% |
|
Tumoral angiogenesis: review of the literature. |
50.00% |
|
Tumor therapy with Amanita phalloides (death cap): stabilization of B-cell chronic lymphatic leukemia. |
90.00% |
|
Tumor pO(2) as a Surrogate Marker to Identify Therapeutic Window during Metronomic Chemotherapy of 9L Gliomas. |
60.00% |
|
Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. |
80.00% |
|
Treatment of locally advanced pancreatic cancer with concurrent uftoral and radiotherapy. Results from 64 patients treated from |
80.00% |
|
Treatment of advanced pancreatic cancer with opioid growth factor: phase I. |
90.00% |
|
Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecula |
80.00% |
|
Trans Arterial Chemo Embolization(TACE) |
40.00% |
|
Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. |
50.00% |
|
Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. |
80.00% |
|
Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expressio |
80.00% |
|
Todoxin, the immune stimulant from Serbia |
86.36% |
|
Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors. |
50.00% |
|
Therapeutic vaccination with an autologous TriMix-Dendritic cell vaccine combined with sequential interferon alfa-2b in ........ |
90.00% |
|
Therapeutic vaccination against advanced pancreatic cancer by autologous dendritic cells pulsed with a MUC1 peptide: Preclinic.. |
60.00% |
|
Therapeutic Potential of Amanitin-Conjugated Anti-Epithelial Cell Adhesion Molecule Monoclonal Antibody Against Pancreatic Carci |
|
|
Theoretical grounds and experimental confirmation of the antiviral effect of the |
60.00% |
|
The way ‘Covid deaths’ are being counted is a national scandal |
80.00% |
|
The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhib |
|
|
The use of mushroom glucans and proteoglycans in cancer treatment. |
90.00% |
|
The story of the cancer medicine Ukrain and Wassil Nowicky |
55.00% |
|
The Result of Vitamin C Treatment of Patients with Cancer: Conditions Influencing the Effectiveness |
60.00% |
|
The present state of antineoplaston research (1) |
90.00% |
|
The PEP-C regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. |
90.00% |
|
The Noscapine Chronicle: A Pharmaco-Historic Biography of the Opiate Alkaloid Family and its Clinical Applications |
90.00% |
|
The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder. |
80.00% |
|
The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alp |
90.00% |
|
The inhibition of glioma growth in vitro and in vivo by a chitosan/ellagic acid composite biomaterial. |
70.00% |
|
The influence of Ukrain on the growth of HA-1 tumor in mice: the role of cysteine proteinases as markers of tumor malignancy |
30.00% |
|
The influence of the novel drug Ukrain on hemo- and immunopoiesis at the time of its maximum radioprotective effect |
60.00% |
|
The influence of glucose, succinate, pH of the medium and higher temperature on the cytotoxic activity of the preparation Ukrain |
80.00% |
|
The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing |
|
|
The incidence and relative risk factors for developing cancer among patients with schizophrenia: a nine-year follow-up study. |
80.00% |
|
The immunomodulating preparation Ukrain does not induce anaphylactic sensitization in mice and guinea pigs |
20.00% |
|
The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary stu |
60.00% |
|
The emerging low-dose therapy for advanced cancers. |
80.00% |
|
The efficacy of corticosteroids in restoring hearing in patients undergoing conservative management of acoustic neuromas.' |
70.00% |
|
The effects of thiophosphoric acid (Ukrain) on cervical cancer, stage IB bulky |
60.00% |
|
The effects of chelidonine on tubulin polymerisation, cell cycle progression and selected signal transmission pathways |
70.00% |
|
The effect of whole-body hyperthermia combined with 'metronomic' chemotherapy on rat mammary adenocarcinoma metastases. |
80.00% |
|
The dynamics of concentration of the main fluorescent component of Ukrain in the tissues and blood plasma of rats with W-256 ... |
80.00% |
|
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline |
70.00% |
|
The antimitotic effects of Ukrain, a Chelidonium majus alkaloid derivative, are reversible in vitro. |
80.00% |
|
The antifungal drug itraconazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, trafficking and |
80.00% |
|
The anti-angiogenic basis of metronomic chemotherapy. |
85.00% |
|
Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse |
80.00% |
|
Teratological evaluation of Ukrain in hamsters and rats |
|
|
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Onco |
40.00% |
|
Targeting tumors with nonreplicating Toxoplasma gondii uracil auxotroph vaccines |
70.00% |
|
Targeting GIPC/synectin in pancreatic cancer inhibits tumor growth. |
30.00% |
|
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer |
70.00% |
|
Systems biology: a therapeutic target for tumor therapy. |
86.67% |
|
Systemic delivery of microencapsulated 3-bromopyruvate for the therapy of pancreatic cancer. |
90.00% |
|
Systemic chemotherapy using paclitaxel and carboplatin plus regional hyperthermia and hyperbaric oxygen treatment for NSCLC. |
70.00% |
|
Systematic review: Cyclo-oxygenase-2 in human oesophageal adenocarcinogenesis. |
50.00% |
|
Systematic review of the treatment of cancer-associated anorexia and weight loss. |
60.00% |
|
Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growt |
80.00% |
|
Synergistic cytotoxicity of artemisinin and sodium butyrate on human cancer cells. |
70.00% |
|
Synergistic antitumor effect of dichloroacetate in combination with 5-fluorouracil in colorectal cancer. |
60.00% |
|
Synchronization of cortisol circadian rhythm by the pineal hormone melatonin in untreatable metastatic solid tumor patients and |
60.00% |
|
Survivin and pancreatic cancer. |
60.00% |
|
Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes |
70.00% |
|
Strong synergy of heat and modulated electromagnetic field in tumor cell killing. |
60.00% |
|
Stoppa Massmordet! |
100.00% |
